Delivery Order SPE2DB22D9304-SPE2DB26FSSG9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $18,868.32 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The contract, issued on November 6, 2025, with an ultimate completion date of November 7, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order represents one of numerous purchase orders...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,474.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 50-25-37.5 mg/75 mg tablets (84 count). This delivery order, issued November 4, 2025, with an ultimate completion date of November 5, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in...
- The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The Defense Logistics Agency awarded a $36,976.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count unit dose packaging). The delivery order, issued on November 5, 2025, with an ultimate completion date of November 6, 2025, carries no set-aside designation, indicating the award was made through full and open competition. DMS...
- The Defense Logistics Agency awarded a $18,488.12 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). The delivery order, issued on June 30, 2025, with an ultimate completion date of July 1, 2025, was awarded without set-aside designation. DMS Pharmaceutical Group leverages its status as a woman-owned small business to compete...
- The Defense Logistics Agency awarded a delivery order valued at $38,633.14 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg tablets in quantities of 14 packets. The delivery order, issued on October 23, 2025, with an ultimate completion date of October 24, 2025, operates under a firm fixed-price structure with no set-aside designation. This award represents a single transaction within...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,976.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on October 27, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order falls...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets. The contract, which became effective on August 1, 2025, with an ultimate completion date of August 4, 2025, was issued without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a $18,488.12 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). This firm fixed-price delivery order, issued on September 25, 2025, with an ultimate completion date of September 26, 2025, operates under DMS Pharmaceutical Group's larger $499.999 billion Indefinite Delivery Contract with the Defense...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $19,316.57 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order, issued on April 24, 2025, with an ultimate completion date of April 25, 2025, calls for the supply of Trikafta 100-50-75 mg/75 mg packets in quantities of 14. This award was issued without a set-aside designation, allowing the vendor to compete on an open basis...
- SPE2DB22D9304Indefinite Delivery Contract
- SPE2DB22D9304-SPE2DB26FSSG9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,488.12 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Trikafta 100-50-75 mg/150 mg tablets (84-count units). Issued on November 6, 2025, with an ultimate completion date of November 7, 2025, this firm fixed-price delivery order carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the Department of Defense pharmaceutical supply chain, leveraging its small business status to compete effectively while maintaining consistent contract performance across multiple therapeutic categories. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy. The parent IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, authorizing DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products to support recurring medical supply needs of military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance on numerous prior delivery orders demonstrates its capability to fulfill the diverse and specialized pharmaceutical requirements of the federal military medical system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.5k | 11/6/25 |